Beyond Arousal: Rethinking Recovery Endpoints in Flumazenil Reversal of Remimazolam [Letter]
Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-2
DOI: 10.2147/dddt.s664435 ↗Kurz gefasst
Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Shuai Miao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanji…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Anesthesiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of Chi…
ORCID-Profile: Shuai Miao, Xin Zhang
Zitieren
APA
Miao, S., Yin, W., & Zhang, X. (2026). Beyond Arousal: Rethinking Recovery Endpoints in Flumazenil Reversal of Remimazolam [Letter]. Drug Design, Development and Therapy, Volume 20, 1-2. https://doi.org/10.2147/dddt.s664435
Vancouver
Miao S, Yin W, Zhang X. Beyond Arousal: Rethinking Recovery Endpoints in Flumazenil Reversal of Remimazolam [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-2. doi:10.2147/dddt.s664435
BibTeX
@article{Miao2026,
author = {Miao, Shuai and Yin, Wenyue and Zhang, Xin},
title = {Beyond Arousal: Rethinking Recovery Endpoints in Flumazenil Reversal of Remimazolam [Letter]},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--2},
doi = {10.2147/dddt.s664435}
}
EUVIMED